Peer-influenced content. Sources you trust. No registration required. This is HCN.

Medical Professionals Reference (MPR)Lawmakers Want to Tighten Access to Veterinary Drug Xylazine

The DEA has issued a warning after discovering xylazine, a tranquilizer for large animals, in almost 25% of the fentanyl powder it seized in 2022. Extensive, necrotic skin ulcerations brought on by xylazine can even result in amputation due to the drug’s ability to impair breathing and cause overdoses. The Combating Illicit Xylazine Act would reclassify the drug as a Schedule III drug, designate it as an emerging threat, and give the DEA the ability to monitor the drug’s production.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form